Last reviewed · How we verify

NCT04623788: MEMORY

Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)

Completed Last updated 23 May 2024
What this trial tests

trial testing Cardiac MRI in Myocarditis in 51 participants. Completed in 2 June 2023.

Timeline
20 February 2020
Primary endpoint
2 June 2023
2 June 2023

Quick facts

Lead sponsorUniversity of Edinburgh
StatusCompleted
Study typeOBSERVATIONAL
Enrollment51
Start date20 February 2020
Primary completion2 June 2023
Estimated completion2 June 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Edinburgh

Who can join

18 and older, any sex, with Myocarditis or Takotsubo Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Manganese is a calcium analogue which actively enters viable cells with intact calcium-handling mechanisms and its uptake is evident by an increase in MRI-detectable T1 relaxivity of tissues. Mangafodipir is a novel manganese-based magnetic resonance imaging (MRI) contrast medium with unique biophysical properties that are ideal for application to cardiac imaging. Recent studies in man have demonstrated the utility of manganese-enhanced MRI (MEMRI) in assessing infarct size more accurately than with standard cardiac MRI protocols using gadolinium enhancement and have shown reduced myocardial manganese uptake in patients with cardiomyopathies suggesting abnormal calcium handling. Understanding the potential for myocardial recovery is key in guiding revascularisation therapies in ischaemic cardiomyopathy, in addition to novel therapies used in heart failure. Being able to monitor calcium handling and therefore myocardial function in different types of cardiomyopathies has the potential to guide management in these patients. The investigators here propose an investigational observational study of MEMRI to assess myocardial calcium handling in reversible causes of cardiomyopathy, namely ischaemic cardiomyopathy, myocarditis and takotsubo cardiomyopathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cardiac MRI

Trials testing the same drug.

Other recruiting trials for Myocarditis

Currently open trials in the same condition.

Other University of Edinburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04623788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing